Advertisement
Petros Pharmaceuticals, Inc. (PTPI)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
As of 02:43PM EDT. Market open.
| Previous Close | 0.4197 |
| Open | 0.4180 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.3564 - 0.4299 |
| 52 Week Range | 0.2820 - 2.2700 |
| Volume | |
| Avg. Volume | 185,984 |
| Market Cap | 3.574M |
| Beta (5Y Monthly) | 2.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.2500 |
| Earnings Date | May 17, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.00 |
ACCESSWIREPetros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussions NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company ...
- ACCESSWIRE
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ("OTC") drug development programs, announces today that Fady Boctor, ...
Simply Wall St.Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
Petros Pharmaceuticals ( NASDAQ:PTPI ) Second Quarter 2024 Results Key Financial Results Revenue: US$1.42m (down 29...
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.